instruction stringlengths 1.05k 19.6k | prompt stringclasses 1
value | output stringlengths 45 233 |
|---|---|---|
{'Official Title': 'A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab vs Placebo in Participants With Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse', 'Brief Summary': 'The purpose of this study is to ... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Exclude: PD-1, PD-L1, PD-L2, CTLA-4'} |
{'Official Title': 'A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab vs Placebo in Participants With Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse', 'Brief Summary': 'The purpose of this study is to ... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Exclude: PD-1, PD-L1, PD-L2, CTLA-4'} |
{'Official Title': 'A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab vs Placebo in Participants With Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse', 'Brief Summary': 'The purpose of this study is to ... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Exclude: PD-1, PD-L1, PD-L2, CTLA-4'} |
{'Official Title': 'A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab vs Placebo in Participants With Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse', 'Brief Summary': 'The purpose of this study is to ... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Exclude: PD-1, PD-L1, PD-L2, CTLA-4'} |
{'Official Title': 'A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab vs Placebo in Participants With Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse', 'Brief Summary': 'The purpose of this study is to ... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Exclude: PD-1, PD-L1, PD-L2, CTLA-4'} |
{'Official Title': 'International,Multicenter,Randomized,Open-label, Phase II to Evaluate the Efficacy and Safety of Continuation of Palbociclib+2nd Line Endocrine Therapy in HR+/HER2- ABC Patients Who Had Clinical Benefit During 1st Line Palbociclib.', 'Brief Summary': 'Hormone Receptor (HR)-positive/Human Epidermal G... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: HR+, HER2- Exclude: HER2+'} |
{'Official Title': 'International,Multicenter,Randomized,Open-label, Phase II to Evaluate the Efficacy and Safety of Continuation of Palbociclib+2nd Line Endocrine Therapy in HR+/HER2- ABC Patients Who Had Clinical Benefit During 1st Line Palbociclib.', 'Brief Summary': 'Hormone Receptor (HR)-positive/Human Epidermal G... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: HR+, HER2- Exclude: HER2+'} |
{'Official Title': 'A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)', 'Brief Summary': 'The purpose of this study is to ev... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: EGFR mutation, specifically either DEL19 or L858R, confirmed acquired T790M mutation'} |
{'Official Title': 'A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)', 'Brief Summary': 'The purpose of this study is to ev... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: EGFR mutation, specifically either DEL19 or L858R, confirmed acquired T790M mutation'} |
{'Official Title': 'A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Various Regimens of Erdafitinib in Subjects With Metastatic or Locally Advanced Urothelial Cancer', 'Brief Summary': 'The purpose of this study is to: (a) characterize the safety and tolerability of and to ide... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: Fibroblast growth factor receptor (FGFR) gene alterations '} |
{'Official Title': 'A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Various Regimens of Erdafitinib in Subjects With Metastatic or Locally Advanced Urothelial Cancer', 'Brief Summary': 'The purpose of this study is to: (a) characterize the safety and tolerability of and to ide... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: Fibroblast growth factor receptor (FGFR) gene alterations '} |
{'Official Title': 'A Phase II Study to Evaluate Neoadjuvant Osimertinib Therapy in Patients With Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer', 'Brief Summary': 'This phase II trial studies how well osimertinib works in treating participants with stage I-IIIA Epithelial Growth Factor Receptor (EGFR) -... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: EGFR mutation (Exon 19 deletion, T790M, or L858R) on tumor samples'} |
{'Official Title': 'A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer', 'Brief Sum... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: HR-Positive, HER2-Negative'} |
{'Official Title': 'A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer', 'Brief Sum... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: HR-Positive, HER2-Negative'} |
{'Official Title': 'A Phase II Study of U3-1402 in Patients With Metastatic Breast Cancer', 'Brief Summary': 'This study is to evaluate safety and efficacy of an antibody drug conjugate U3-1402 in patients with locally advanced or metastatic breast cancer (MBC).', 'Condition': 'Metastatic Breast Cancer Locally Advanced... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: HER2-Negative, HR-Positive Exclude: HER2-positive'} |
{'Official Title': 'A Phase II Study of U3-1402 in Patients With Metastatic Breast Cancer', 'Brief Summary': 'This study is to evaluate safety and efficacy of an antibody drug conjugate U3-1402 in patients with locally advanced or metastatic breast cancer (MBC).', 'Condition': 'Metastatic Breast Cancer Locally Advanced... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: HER2-Negative, HR-Positive, Regardless of HER3 expression Exclude: HER2-positive'} |
{'Official Title': 'A Phase II Study of U3-1402 in Patients With Metastatic Breast Cancer', 'Brief Summary': 'This study is to evaluate safety and efficacy of an antibody drug conjugate U3-1402 in patients with locally advanced or metastatic breast cancer (MBC).', 'Condition': 'Metastatic Breast Cancer Locally Advanced... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: HER2-Positive Exclude:HER2-Negative'} |
{'Official Title': 'A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C', 'Brief Summary': 'A Phase 3 Study to Compare AMG 510 with Docetaxel in... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'KRASG12C mutated'} |
{'Official Title': 'A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C', 'Brief Summary': 'A Phase 3 Study to Compare AMG 510 with Docetaxel in... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'KRASG12C mutated'} |
{'Official Title': 'A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)', 'Brief Summary': 'This is a Phase Ib/II, open-label, multicenter, randomized umbrella... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: PD-L1'} |
{'Official Title': 'A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)', 'Brief Summary': 'This is a Phase Ib/II, open-label, multicenter, randomized umbrella... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: PD-L1'} |
{'Official Title': 'A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)', 'Brief Summary': 'This is a Phase Ib/II, open-label, multicenter, randomized umbrella... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: PD-L1'} |
{'Official Title': 'A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)', 'Brief Summary': 'This is a Phase Ib/II, open-label, multicenter, randomized umbrella... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: PD-L1'} |
{'Official Title': 'A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)', 'Brief Summary': 'This is a Phase Ib/II, open-label, multicenter, randomized umbrella... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: PD-L1'} |
{'Official Title': 'A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)', 'Brief Summary': 'This is a Phase Ib/II, open-label, multicenter, randomized umbrella... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: PD-L1'} |
{'Official Title': 'A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)', 'Brief Summary': 'This is a Phase Ib/II, open-label, multicenter, randomized umbrella... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: PD-L1'} |
{'Official Title': 'A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)', 'Brief Summary': 'This is a Phase Ib/II, open-label, multicenter, randomized umbrella... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: PD-L1'} |
{'Official Title': 'A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1', 'Brief Summary': 'This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advance... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: KRAS G12C mutation'} |
{'Official Title': 'A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1', 'Brief Summary': 'This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advance... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: KRAS G12C mutation'} |
{'Official Title': 'A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1', 'Brief Summary': 'This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advance... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: KRAS G12C mutation'} |
{'Official Title': 'A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1', 'Brief Summary': 'This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advance... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: KRAS G12C mutation'} |
{'Official Title': 'A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1', 'Brief Summary': 'This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advance... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: KRAS G12C mutation'} |
{'Official Title': 'A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1', 'Brief Summary': 'This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advance... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: KRAS G12C mutation'} |
{'Official Title': 'A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1', 'Brief Summary': 'This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advance... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: KRAS G12C mutation'} |
{'Official Title': 'A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1', 'Brief Summary': 'This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advance... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: KRAS G12C mutation'} |
{'Official Title': 'A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1', 'Brief Summary': 'This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advance... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: KRAS G12C mutation'} |
{'Official Title': 'A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O).', 'Brief Summary': 'This is a Phase II... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: BRCA1/2 mutation'} |
{'Official Title': 'A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O).', 'Brief Summary': 'This is a Phase II... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: BRCA1/2 mutation'} |
{'Official Title': 'A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O).', 'Brief Summary': 'This is a Phase II... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: BRCA1/2 mutation'} |
{'Official Title': 'A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O).', 'Brief Summary': 'This is a Phase II... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: BRCA1/2 mutation'} |
{'Official Title': 'A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Study to Evaluate the Efficacy and Safety of Toripalimab Injection (JS001) or Placebo Combined With First-line Standard Chemotherapy in Treatment-naive Advanced Non-small Cell Lung Cancer (NSCLC)', 'Brief Summary': 'Thi... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: PD-L1 expression'} |
{'Official Title': 'A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Study to Evaluate the Efficacy and Safety of Toripalimab Injection (JS001) or Placebo Combined With First-line Standard Chemotherapy in Treatment-naive Advanced Non-small Cell Lung Cancer (NSCLC)', 'Brief Summary': 'Thi... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: PD-L1 expression'} |
{'Official Title': 'A Phase 2b, Open-label, Single-arm Study of ZW25 Monotherapy in Subjects With Advanced or Metastatic HER2-amplified Biliary Tract Cancers', 'Brief Summary': 'This multicenter, open-label, single-arm trial will evaluate the anti-tumor activity of ZW25 (zanidatamab) monotherapy in subjects with human ... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: HER2 Amplification '} |
{'Official Title': 'Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma (Phase I and II) and Other Solid Tumors (Phase I Only)', 'Brief Summary': 'This phase I/II trial studies the side effects and best dose of dabrafenib, trametinib, and navitoclax and to see how well they work in treati... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: BRAF-mutant (V600E/K)'} |
{'Official Title': 'Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma (Phase I and II) and Other Solid Tumors (Phase I Only)', 'Brief Summary': 'This phase I/II trial studies the side effects and best dose of dabrafenib, trametinib, and navitoclax and to see how well they work in treati... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: BRAF-mutant (V600E/K)'} |
{'Official Title': 'Efficacy and Safety of Neoadjuvant Therapy of Pembrolizumab Combined With Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer: An Open-label Single-arm Phase II Study', 'Brief Summary': 'The efficacy and safety of the neoadjuvant therapy of pembrolizumab+ ramucirumab', 'Condition': 'Non-small C... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: PD-L1-Positive'} |
{'Official Title': 'A Phase Ib/II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation', 'Brief Summary': 'This is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ4... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: KRAS G12C mutant Exclude: Tumors harboring driver mutations that have approved targeted therapies, with the exception of KRAS G12C mutations'} |
{'Official Title': 'A Phase Ib/II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation', 'Brief Summary': 'This is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ4... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: KRAS G12C mutant Exclude: Tumors harboring driver mutations that have approved targeted therapies, with the exception of KRAS G12C mutations'} |
{'Official Title': 'A Phase Ib/II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation', 'Brief Summary': 'This is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ4... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: KRAS G12C mutant Exclude: Tumors harboring driver mutations that have approved targeted therapies, with the exception of KRAS G12C mutations'} |
{'Official Title': 'A Phase Ib/II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation', 'Brief Summary': 'This is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ4... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: KRAS G12C mutant Exclude: Tumors harboring driver mutations that have approved targeted therapies, with the exception of KRAS G12C mutations'} |
{'Official Title': 'FIREFLY-1: A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients With BRAF-Altered, Recurrent or Progressive Low-Grade Glioma and Advanced Solid Tumors', 'Brief Summary': 'FIREFLY-1 is a Phase 2, multi center, open-lab... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'BRAF or CRAF/RAF1 fusion or BRAF V600 mutations and KIAA1549:BRAF fusions'} |
{'Official Title': 'FIREFLY-1: A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients With BRAF-Altered, Recurrent or Progressive Low-Grade Glioma and Advanced Solid Tumors', 'Brief Summary': 'FIREFLY-1 is a Phase 2, multi center, open-lab... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'BRAF or CRAF/RAF1 fusion or BRAF V600 mutations and KIAA1549:BRAF fusions'} |
{'Official Title': 'FIREFLY-1: A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients With BRAF-Altered, Recurrent or Progressive Low-Grade Glioma and Advanced Solid Tumors', 'Brief Summary': 'FIREFLY-1 is a Phase 2, multi center, open-lab... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'BRAF or CRAF/RAF1 fusion or BRAF V600 mutations and KIAA1549:BRAF fusions'} |
{'Official Title': 'PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer', 'Brief ... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: ER+ and/or PR+, HER2-'} |
{'Official Title': 'PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer', 'Brief ... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: ER+ and/or PR+, HER2-'} |
{'Official Title': 'A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects With Advanced Urothelial Cancer and Selected FGFR Gene Aberrations', 'Brief Summary': 'The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participan... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: fibroblast growth factor receptor (FGFR) aberrations'} |
{'Official Title': 'A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects With Advanced Urothelial Cancer and Selected FGFR Gene Aberrations', 'Brief Summary': 'The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participan... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: fibroblast growth factor receptor (FGFR) aberrations'} |
{'Official Title': 'A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects With Advanced Urothelial Cancer and Selected FGFR Gene Aberrations', 'Brief Summary': 'The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participan... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: fibroblast growth factor receptor (FGFR) aberrations'} |
{'Official Title': 'A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects With Advanced Urothelial Cancer and Selected FGFR Gene Aberrations', 'Brief Summary': 'The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participan... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: fibroblast growth factor receptor (FGFR) aberrations'} |
{'Official Title': 'A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Clinical Study on Toripalimab Combined With Platinum-Based Doublet Drug Chemotherapy for Resectable, Stage II-III, Non-Small Cell Lung Cancer', 'Brief Summary': 'This is a randomized, double-blind, placebo-controlled, multi-cente... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include : PD-L1 Exclude : EGFR sensitive mutations, ALK translocation'} |
{'Official Title': 'A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Clinical Study on Toripalimab Combined With Platinum-Based Doublet Drug Chemotherapy for Resectable, Stage II-III, Non-Small Cell Lung Cancer', 'Brief Summary': 'This is a randomized, double-blind, placebo-controlled, multi-cente... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include : PD-L1 Exclude : EGFR sensitive mutations, ALK translocation'} |
{'Official Title': 'A Phase 2, Multicenter, Randomized, Study of Trastuzumab Deruxtecan in Participants With HER2-overexpressing Locally Advanced, Unresectable or Metastatic Colorectal Cancer (DESTINY-CRC02)', 'Brief Summary': 'This study will evaluate the efficacy, safety, and pharmacokinetics of Trastuzumab deruxteca... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: HER2-Overexpressing, BRAF Wild-type'} |
{'Official Title': 'A Phase 2, Multicenter, Randomized, Study of Trastuzumab Deruxtecan in Participants With HER2-overexpressing Locally Advanced, Unresectable or Metastatic Colorectal Cancer (DESTINY-CRC02)', 'Brief Summary': 'This study will evaluate the efficacy, safety, and pharmacokinetics of Trastuzumab deruxteca... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: HER2-Overexpressing, BRAF Wild-type'} |
{'Official Title': 'Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)', 'Brief Summary': "This phase II trial studies whether atezolizumab in combination with talazoparib works bette... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: SLFN11-Positive'} |
{'Official Title': 'Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)', 'Brief Summary': "This phase II trial studies whether atezolizumab in combination with talazoparib works bette... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: SLFN11-Positive'} |
{'Official Title': 'A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)', 'Brief Summary': 'This is an open-label, multi-center, multi-cohort, Phase 2 study to evaluate the effi... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: HER2-Expressing, Exclude: known Somatic DNA mutation of HER2 without tumoral HER2 protein expression'} |
{'Official Title': 'A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)', 'Brief Summary': 'This is an open-label, multi-center, multi-cohort, Phase 2 study to evaluate the effi... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: HER2-Expressing, Exclude: known Somatic DNA mutation of HER2 without tumoral HER2 protein expression'} |
{'Official Title': 'A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)', 'Brief Summary': 'This is an open-label, multi-center, multi-cohort, Phase 2 study to evaluate the effi... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: HER2-Expressing, Exclude: known Somatic DNA mutation of HER2 without tumoral HER2 protein expression'} |
{'Official Title': 'A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)', 'Brief Summary': 'This is an open-label, multi-center, multi-cohort, Phase 2 study to evaluate the effi... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: HER2-Expressing, Exclude: known Somatic DNA mutation of HER2 without tumoral HER2 protein expression'} |
{'Official Title': 'A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)', 'Brief Summary': 'This is an open-label, multi-center, multi-cohort, Phase 2 study to evaluate the effi... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: HER2-Expressing, Exclude: known Somatic DNA mutation of HER2 without tumoral HER2 protein expression'} |
{'Official Title': 'A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)', 'Brief Summary': 'This is an open-label, multi-center, multi-cohort, Phase 2 study to evaluate the effi... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: HER2-Expressing, Exclude: known Somatic DNA mutation of HER2 without tumoral HER2 protein expression'} |
{'Official Title': 'A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)', 'Brief Summary': 'This is an open-label, multi-center, multi-cohort, Phase 2 study to evaluate the effi... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: HER2-Expressing, Exclude: known Somatic DNA mutation of HER2 without tumoral HER2 protein expression'} |
{'Official Title': 'Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer.', 'Brief Summary': 'The primary objective of this study is to evaluate 12 weeks progression-free survival (PFS) rate of Palbociclib plus Letrozole in ER/PR positive endome... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: PR-Positive, ER-Positive'} |
{'Official Title': 'Phase II Randomized Study of Maintenance Regorafenib vs Placebo in no Progression Patients After First-line Platinum and Fluoropyrimidines Based Chemotherapy in HER2 Negative Locally Advanced/Metastatic Gastric or Gastroesophagel Junction Cancer (a-MANTRA Study)', 'Brief Summary': 'Randomized, doubl... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: HER2 negative'} |
{'Official Title': 'Phase II Randomized Study of Maintenance Regorafenib vs Placebo in no Progression Patients After First-line Platinum and Fluoropyrimidines Based Chemotherapy in HER2 Negative Locally Advanced/Metastatic Gastric or Gastroesophagel Junction Cancer (a-MANTRA Study)', 'Brief Summary': 'Randomized, doubl... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: HER2 negative'} |
{'Official Title': 'Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes', 'Brief Summary': 'Abstract Study title: Single-center, Multi-cohort Explorato... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: HER2 positive, Claudin 18.2 positive, HER2 negative, Claudin 18.2 negative'} |
{'Official Title': 'Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes', 'Brief Summary': 'Abstract Study title: Single-center, Multi-cohort Explorato... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: HER2 positive, Claudin 18.2 positive, HER2 negative, Claudin 18.2 negative'} |
{'Official Title': 'Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes', 'Brief Summary': 'Abstract Study title: Single-center, Multi-cohort Explorato... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: HER2 positive, Claudin 18.2 positive, HER2 negative, Claudin 18.2 negative'} |
{'Official Title': 'A Phase 2 Open Label Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma Previously Treated With ALK Inhibitors (CRU3)', 'Brief Summary': 'The purpose of this study is to define the objective response rates (ORR) of Lorlatinib in subjects with ALK+ lymphomas resistant or refract... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: ALK positive'} |
{'Official Title': 'A Randomised, Double-blind, Placebo-controlled, Multicentre Phase Ш Clinical Study to Evaluate the Efficacy and Safety of First-line Treatment With SG001 Plus Chemotherapy±Bevacizumab Versus Placebo Plus Chemotherapy±Bevacizumab for PD-L1 Positive (CPS≥1) Women With Recurrent, or Metastatic Cervical... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: PD-L1 positive'} |
{'Official Title': 'A Randomised, Double-blind, Placebo-controlled, Multicentre Phase Ш Clinical Study to Evaluate the Efficacy and Safety of First-line Treatment With SG001 Plus Chemotherapy±Bevacizumab Versus Placebo Plus Chemotherapy±Bevacizumab for PD-L1 Positive (CPS≥1) Women With Recurrent, or Metastatic Cervical... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: PD-L1 positive'} |
{'Official Title': 'An Open Label, Single-Arm, Multi-center Phase Ib/II Study to Evaluate the Safety and Efficacy of INCB054828 in Combination With Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer With FGFs/FGFRs Genetic Aberration.', 'Brief Summary': 'This study was conducted as a second-line... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: FGFs/FGFRs Genetic Aberration'} |
{'Official Title': 'A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination With Durvalumab, Followed by Maintenance Durvalumab With or Without Olaparib in Patients With Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)', 'Brief... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: MMR evaluation.'} |
{'Official Title': 'A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination With Durvalumab, Followed by Maintenance Durvalumab With or Without Olaparib in Patients With Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)', 'Brief... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: MMR evaluation.'} |
{'Official Title': 'A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination With Durvalumab, Followed by Maintenance Durvalumab With or Without Olaparib in Patients With Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)', 'Brief... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: MMR evaluation.'} |
{'Official Title': 'A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)', 'Brief Summary': 'The purpose of this Phase 2/3 study is to evaluate efficacy and safety of the ... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: c-MYC, Bcl2 and/or Bcl6 rearrangements'} |
{'Official Title': 'A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)', 'Brief Summary': 'The purpose of this Phase 2/3 study is to evaluate efficacy and safety of the ... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: c-MYC, Bcl2 and/or Bcl6 rearrangements'} |
{'Official Title': 'A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)', 'Brief Summary': 'The purpose of this Phase 2/3 study is to evaluate efficacy and safety of the ... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: c-MYC, Bcl2 and/or Bcl6 rearrangements'} |
{'Official Title': 'A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)', 'Brief Summary': 'The purpose of this Phase 2/3 study is to evaluate efficacy and safety of the ... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: c-MYC, Bcl2 and/or Bcl6 rearrangements'} |
{'Official Title': 'A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)', 'Brief Summary': 'The purpose of this Phase 2/3 study is to evaluate efficacy and safety of the ... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: c-MYC, Bcl2 and/or Bcl6 rearrangements'} |
{'Official Title': 'A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)', 'Brief Summary': 'The purpose of this Phase 2/3 study is to evaluate efficacy and safety of the ... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: c-MYC, Bcl2 and/or Bcl6 rearrangements'} |
{'Official Title': 'Multicentric Randomized Phase I/II Study to Evaluate Efficacy of Trifluridine/Tipiracil Plus XB2001 (Anti-IL-1α True Human Antibody) Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine', 'Brief Summary': 'Unre... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Exclude: Mutational status BRAF mutant'} |
{'Official Title': 'Multicentric Randomized Phase I/II Study to Evaluate Efficacy of Trifluridine/Tipiracil Plus XB2001 (Anti-IL-1α True Human Antibody) Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine', 'Brief Summary': 'Unre... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Exclude: Mutational status BRAF mutant'} |
{'Official Title': 'A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects With TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy', 'Brief Summary': 'This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who hav... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: TP53WT'} |
{'Official Title': 'A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects With TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy', 'Brief Summary': 'This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who hav... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: TP53WT'} |
{'Official Title': 'A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects With TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy', 'Brief Summary': 'This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who hav... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: TP53WT'} |
{'Official Title': 'A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects With TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy', 'Brief Summary': 'This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who hav... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: TP53WT'} |
{'Official Title': 'A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects With TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy', 'Brief Summary': 'This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who hav... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: TP53WT'} |
{'Official Title': 'A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects With TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy', 'Brief Summary': 'This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who hav... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: TP53WT'} |
{'Official Title': 'A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects With TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy', 'Brief Summary': 'This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who hav... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: TP53WT'} |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.